MODERN METHODS OF ABLATION FOR MALIGNANT LIVER TUMORS (LITERATURE REVIEW)
DOI:
https://doi.org/10.37547/Keywords:
primary liver cancer, hepatocellular carcinoma, hepatic metastases, radiofrequency ablation, microwave ablation, high-intensity focused ultrasound therapy, laser ablation, cryoablation, percutaneous ethanol injection, irreversible electroporation, stereotactic body radiation therapy.Abstract
The purpose of this review is to demonstrate the possibility of performing various methods of thermal and non-thermal ablation in patients with primary and metastatic liver tumors on the basis of data available in the world medical literature.
Downloads
References
1.Kaprin AD, Starinsky VV, Petrova GV. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Moscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation; 2017, 250 p. (In Russian).
2.Kaprin AD, Starinsky VV, Petrova GV. The state of cancer care in Russia in 2017. Moscow: P. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation; 2018, 236 p. (In Russian).
3.Lunev SV, Selchuk VY, Chistyakov SS. Modern approaches to surgical treatment of liver tumors. Russian Medical Journal. 2011;2:44–47.
4.Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a 10-year population-based study of 5,772 patients with primary colorectal adenocarcinoma. BMC Cancer. 2014;14:810. DOI: 10.1186/1471–2407–14–810.
5.de Haas RJ, Wicherts DA, Flores E, Ducreux M, Lévi F, Paule B, et al. Tumor markers versus imaging for assessment of chemotherapy response in patients with colorectal liver metastases. Ann Surg Oncol. 2010;17(4):1010–23. DOI: 10.1245/s10434–009–0887–5.
6.Vishnevsky VA, Efanov MG, Ikramov RZ, Zhao AV. Hepatic tumors: diagnostics and surgical treatment. Russian Journal of Evidence-Based Gastroenterology. 2013;2:38–47.
7.Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.
8.Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. DOI: 10.1056/NEJMoa0708857.
9.Labib PL, Davidson BR, Sharma RA, Pereira SP. Locoregional therapies for cholangiocarcinoma. Hepat Oncol. 2017;4(4):99–109. DOI: 10.2217/hep-2017–0014.
10.Hansen PD, Cassera MA, Wolf RF. Ablative therapies for hepatocellular carcinoma, cholangiocarcinoma, and colorectal liver metastases. Surg Oncol Clin N Am. 2015;24(1):97–119. DOI: 10.1016/j.soc.2014.09.003.
11.Knavel EM, Brace CL. Tumor ablation: common modalities and general practices. Tech Vasc Interv Radiol. 2013;16(4):192–200. DOI: 10.1053/j.tvir.2013.08.002.
12.Napoletano C, Taurino F, Biffoni M, et al. Radiofrequency ablation (RFA) strongly stimulates the immune system and antitumor response in patients with liver metastases. Int J Oncol. 2008;32(2):481–90.
13.Reuter NP, Woodall CE, Scoggins CR, et al. Radiofrequency ablation vs resection for colorectal liver metastases: are they therapeutically equivalent? J Gastrointest Surg. 2009;13(3):486–91. DOI: 10.1007/s11605–008–0727–0.
14.Agcaoglu O, Aliyev S, Karabulut K, et al. Resection versus radiofrequency ablation for colorectal liver metastases: analysis of 395 patients. World J Surg. 2013;37(6):1333–9. DOI: 10.1007/s00268–013–1981–1.
15.Razafindratsira T, Isamber M, Evrard S. Complications of intraoperative radiofrequency ablation for liver metastases. HPB. 2011;13:15–23. DOI: 10.1111/j.1477–2574.2010.00243.x.
16.Berber E, Siperstein A. Local tumor recurrence after laparoscopic radiofrequency ablation: analysis of 1,032 tumors. Ann Surg Oncol. 2008;15(10):2757–64. DOI: 10.1245/s10434–008–0043–7.
17.Nielsen K, van Tilborg AA, Meijerink MR, et al. Local recurrence rates and management after RFA for colorectal liver metastases. World J Surg. 2013;37(6):1340–7. DOI: 10.1007/s00268–013–1997.
18.Van Tilborg AA, Meijerink MR, Sietses C, et al. Long-term results of RFA for unresectable colorectal liver metastases: potential cure. Br J Radiol. 2011;84(1002):556–65. DOI: 10.1259/bjr/78268814.
19.Kim KH, Yoon YS, Yu CS, et al. Comparative analysis of RFA and surgical resection for colorectal liver metastases. J Korean Surg Soc. 2011;81(1):25–34. DOI: 10.4174/jkss.2011.81.1.25.
20.Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic therapy versus systemic therapy alone in unresectable colorectal liver metastases. Ann Oncol. 2012;23(10):2619–26. DOI: 10.1093/annonc/mds053.
21.Ruers T, Van Coevorden F, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases: results of the phase II randomized trial. J Natl Cancer Inst. 2017;109(9). DOI: 10.1093/jnci/djx015.
22.Kim YS, Lim HK, Rhim H, et al. Percutaneous RFA as first-line therapy for early-stage hepatocellular carcinoma: 10-year outcomes and prognostic factors. J Hepatol. 2013;58(1):89–97. DOI: 10.1016/j.jhep.2012.09.020.
